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Abstract: In the majority of castration-resistant prostate cancer (CRPC), prostate-specific 
antigen (PSA), product of a gene that is almost exclusively regulated by the androgen 
receptor (AR), still acts as a serum marker reflecting disease burden, indicating that  
AR signaling is activated even under castrate level of serum androgen. Accumulated 
evidence shows that transcriptional ability of AR is activated both in ligand-dependent and 
-independent manners in CRPC cells. Some androgen-independent sublines derived from 
originally androgen-dependent LNCaP prostate cancer cells overexpress the AR and PSA, 
for which silencing the AR gene suppresses cellular proliferation. The overexpression of 
the AR confers androgen-independent growth ability on androgen-dependent prostate cancer 
cells. Some patient-derived prostate cancer xenograft lines also acquire castration-resistant 
growth ability secreting PSA. More recent publications have shown that the AR activated 
in CRPC cells regulates distinct gene sets from that in androgen-dependent status. This 
concept provides very important insights in the development of novel anti-prostate cancer 
drugs such as new generation anti-androgens and CYP17 inhibitors. 
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1. Clinical Aspects of Castration-Resistant Prostate Cancer 
Although almost all prostate cancers initially respond to androgen-deprivation therapy (ADT) 
comprising medical or surgical castration, ADT is usually not permanently effective or curative, and 
most tumors eventually regrow after a certain period. Before docetaxel was recently proved to improve 
survival of prostate cancer patients after ADT failure [1,2], there had been no effective treatment left, 
and those patients are clinically categorized as a distinct disease stage. At this point, prostate cancers 
appear to have become a “hormone-refractory” disease characterized by “androgen-independent” 
tumor growth. Recent works have shown, however, that prostate cancers continue to depend on 
androgen receptor (AR) signaling despite low serum androgen levels. Consistently, serum  
prostate-specific antigen (PSA), a serine protease coded by a gene that is almost exclusively regulated 
by the AR, still plays a clinically important role as a serum marker reflecting disease burden. 
Therefore, prostate cancers that are progressing after castration are called castration-resistant prostate 
cancer (CRPC) [3,4]. Indeed, recent clinical trials have shown that a new generation anti-androgen [5] 
or novel inhibitor targeting androgen synthesis [6] is effective for post-docetaxel CRPC indicating that 
CRPC at that stage are still, at least in part, dependent on androgen/AR axis. 
Recent works have accumulated direct and indirect evidence indicating that, in CRPC, AR signaling 
is activated even under the castrate level of serum androgen. This concept is very important since it 
means that AR itself and its downstream signaling can be still a therapeutic target in CRPC. However, 
molecular mechanisms for re-activation of AR in CRPC are complex and heterogeneous. Thus, it is 
indispensable to demystify detailed pathways for castration-resistant progression of prostate cancer. 
This review outlines recent advances in prostate cancer research and experimental evidence for the 
essential role of AR in CRPC. 
2. AR Signaling Axis and Androgen Deprivation 
In hormone-naive status, androgens circulate in blood in either a bound (to albumin or  
sex-hormone-binding protein) or free form. The majority (~95%) of circulating androgens is 
testosterone, produced by Leydig cells in testis under control of the pituitary hormone luteinizing 
hormone (LH). Free serum testosterone can transfer across plasma membrane into cytoplasm of 
prostatic epithelial cells, where unbound AR is abundant. Testosterone is then reduced by 5α-reductase 
into dihydrotestosterone (DHT), a more potent form of AR ligand. Upon binding of androgen, AR 
translocates to nucleus in a dimerized form and regulates gene expression by binding to specific 
hormone response elements. 
Normal prostate epithelium and most of untreated prostate cancer cells are highly dependent on the 
androgen/AR axis and ablation or blockade of the signaling pathway results in severe regression of the 
tissue. Prostatic epithelial cells in culture stop proliferating at G1 cell-cycle phase (G1 arrest) upon 
androgen deprivation and then go to apoptosis. With the exception of rare small cell carcinomas of the 
prostate, most untreated human prostate cancers express AR at both the mRNA and protein level and 
respond to ADT. Physiologically, 95% of serum androgens are produced by testicular Leydig cells, 
while the rest are secreted by the adrenal gland. In ADT, surgical castration by bilateral orchiectomy, 
or medical castration by the administration of luteinizing hormone-releasing hormone analogue (either 
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agonist or antagonist), suppress serum testosterone levels. Combined androgen blockade (CAB) 
comprises administration of an anti-androgen and surgical or medical castration. Castration suppresses 
serum testicular androgen levels and residual testicular and adrenal androgens are blocked  
by anti-androgens. 
3. AR-Independent Pathways for CRPC 
Molecular mechanisms for CRPC that progresses, by definition, despite castrate levels of serum 
testosterone can be categorized into roughly two concepts, namely AR-independent and -dependent 
pathways. AR-independent pathway, which is beyond the scope of this review, includes AR-independent 
activation of survival or anti-apoptotic pathway and mechanisms involving subpopulation of 
intrinsically AR-independent cancer cells. It has been known that androgen ablation induce activation 
of anti-apoptotic molecules such as BCL-2 [7], Clusterin [8], and AKT [9], which leads to the 
resistance by prostate cancer cells to castration. Some investigators reported that these pathways are 
promising therapeutic targets in CRPC [9–11]. 
The presence of a primarily AR-independent subpopulation in prostate cancer cells has long been 
suggested as a potential mechanism for castration-resistant progression of prostate cancer [12]. 
Although attractive, it has been only one theoretical model, and the presence of castration-resistant mouse 
prostatic epithelial cells has been documented recently [13]. Surprisingly, those are not basal cells as 
postulated initially but of luminal origin. It is still controversial which of luminal or basal epithelium is 
the cell of origin of prostatic adenocarcinoma, whether intrinsically castration-resistant luminal cells 
exist in human normal and malignant prostatic tissue, and whether the inherent castration-resistant 
subpopulation, if any, has a role in castration-resistant progression of prostate cancer. 
4. AR-Dependent Pathways for CRPC 
Thus, there is certainly an AR-independent subset of CRPC, however they are considered as a small 
minority, whereas the vast majority of CRPC maintain AR-mediated signaling activity and dependence 
on it. Reactivation of AR signaling in CRPC is clinically evident by re-elevation of PSA in most cases, 
and there is a response to secondary or tertiary hormonal therapy in the majority of them. Additionally, 
constant nuclear expression of AR in CRPC cells indicates that the AR signaling remains active 
despite the androgen withdrawal [14]. It is further supported by experimental findings that, in some  
models [15,16] as well as human surgical specimens [16–19], CRPC tumors express AR-targeted 
genes despite androgen ablation. Accumulated experimental evidence indicates that there are various 
mechanisms for the activation of an AR-mediated signaling axis under castrated conditions. They 
include de novo ectopic androgen synthesis and AR hypersensitivity or promiscuous activation  
caused by overexpression, mutation or truncation, interaction with co-factors, and posttranslational 
modifications. These discoveries have led to the development and introduction of novel therapeutic 
agents targeting the AR signaling axis toward clinical use. 
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5. De Novo Synthesis of Androgen (Figure 1A) 
Expression profiles of castration-resistant tumors by Holzbeierlein and colleagues demonstrated 
that the gene expression changes detected in response to androgen ablation therapy were no longer 
present and that many of AR-driven genes were expressed, suggesting a reactivation of the androgen 
response pathway in the absence of exogenous androgen [15]. It was reported that castration-resistant 
bone marrow metastasis tumors [16] and circulating tumor cells from CRPC patients [17] express  
AR-regulated genes, indicating persistent activation of the AR signaling axis despite castration. 
Additionally, an increased expression of genes encoding steroidogenic enzymes was observed in these 
tissues and cells [16,17]. 
Locke and colleagues demonstrated intratumoral de novo synthesis of DHT in the LNCaP xenograft 
model for CRPC using liquid chromatography-radiometric/mass spectrometry (LC/MS) technique [18]. 
LNCaP tumors expressed all enzymes necessary to synthesize androgen and intratumoral androgens 
increased during CRPC progression in correlation to PSA upregulation. Montgomery and colleagues 
examined human hormone-naive and castration resistant metastatic prostate cancer tissue using 
LC/MS and found that the tissue testosterone level is higher in CRPC [19]. CRPC also displayed 
upregulation of genes encoding steroidogenic enzymes including CYP17A1, HSD3B1, HSD17B3, 
CYP19A1 and UGT2B17. These results clearly indicate that, despite anorchid serum testosterone 
levels, intratumoral steroidogenesis permits tumors to castration-resistant progression. These 
experimental findings drove researchers to develop inhibitors of androgenic enzymes and indeed 
abiraterone acetate, a CYP17 inhibitor, has been shown to improve survival of CRPC patients [6] and 
approved by the US Food and Drug Administration (FDA) for clinical use. Another CYP17 inhibitor, 
TAK700, is also currently under clinical trial [20]. 
6. AR Overexpression (Figure 1B) 
One of the hallmarks of CRPC is overexpression of AR. A number of reports have shown  
increased expression of AR in human CRPC tissues based on gene expression [21–35] and 
immunohistochemistry [31,32] as well as circulating tumor cells from CRPC patients [17,36–38], 
although inconsistent results have been reported for a significant association between high AR 
expression and clinical outcomes [26,31,34]. High AR expression in CRPC is reproducible in some 
experimental models based on cell lines [39], cell line-based xenograft lines [40,41], and  
patient-derived tumor graft lines [42,43]. In a series from Erasmus Medical Center, Rotterdam, the 
Netherlands, the authors analyzed androgen dependent PC346 human prostate cancer cells expressing 
wild-type AR [39]. They further established sublines including those with acquired resistance to 
various androgen blockade therapies and found some of them overexpress AR and PSA. Chen and 
colleagues compared seven castration-resistant cell-based xenograft lines with their parental androgen 
sensitive lines and found that all seven tumors after castration-resistant progression showed modest 
increase in AR protein expression [40]. Our group has established sequentially transplantable 
xenograft lines from CRPC tissues that represent clinical features of prostate cancer including 
androgen sensitive regression upon castration followed by castration-resistant regrowth [42,43]. 
Notably, tumors in castration-resistant status overexpress AR protein. As a consequence of 
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overexpression, increased AR sensitizes prostate cancer cells to low levels of androgen, leading to 
castration-resistant progression [40,44]. 
AR gene amplification partly accounts for the high expression of AR in some CRPC cases. 
Although AR plays an essential role in the carcinogenesis of prostate cancer, only a small minority of 
untreated prostate cancers harbor copy number alteration of AR gene [29,30,35,45,46]. In contrast,  
10%–80% of CRPC cases have copy number gain of AR gene [23,24,26,27,31–33,35,37,45,46], 
indicating AR gene amplification is a driving force for castration-resistant progression of prostate 
cancer in those cases. Other possible explanations for AR overexpression include increased expression 
of AR gene without amplification (see an excellent review by Shiota et al. [47]) as well as 
posttranscriptional and posttranslational regulations of AR. 
As for posttranscriptional modification, Yeap and colleagues demonstrated that AR mRNA stability 
is a major determinant of AR gene expression in prostate and breast cancer cells [48] and identified 
several RNA-binding proteins including HuA, CP1 and CP2 which bind to a highly conserved UC-rich 
region of 3'-UTR of AR mRNA and affect stabilization of AR mRNA [49]. Another group identified 
EBP1 as an RNA-binding protein that binds to the UC-rich region of the 3'-untranslated region  
(3'-UTR) of AR mRNA and stabilizes it [50]. 
Micro RNAs (miRNAs) modulate translation of mRNA by base-pairing interactions with 3'-UTR 
through destabilizing the mRNA or by repression of protein synthesis in actively translating 
ribosomes. However, association between miRNA-mediated regulation of AR and development of 
CRPC had not been evident until very recently [51]. A systematic analysis based on a gain-of-function 
screening of 1129 miRNAs by Ostling and colleagues identified 71 unique miRNAs that influenced 
the level of AR in human prostate cancer cells [52]. Of those, miR-34a and miR-34c expression was 
negatively associated with AR levels based on analysis of clinical prostate cancers. Another group has 
demonstrated that the overexpression of miR-488* downregulated the transcriptional activity of AR 
and inhibits the endogenous AR protein production in human prostate cancer cells [53]. Those results 
suggested that suppression of AR-targeting miRNAs may promote CRPC, although therapeutic 
potential of targeting these pathways is not fully understood. 
AR is regulated also in posttranslational manners. It has been known that half-life of AR  
protein is prolonged in the presence of agonistic steroids including testosterone, dihydrotestosterone,  
R1881 (synthetic androgen), and other nonandrogenic steroids in prostate cancer cells [54,55] and 
others [56–60]. Effectiveness of stabilization is correlated with affinity of ligands to AR and abolished 
by AR antagonists including hydroxyflutamide and bicalutamide [57,59]. Stabilization of AR increases 
abundance of AR protein and usually promotes androgen-dependent proliferation. However, it was 
reported that AR needs to be degraded during mitosis for subsequent cell-cycle progression and too 
much stabilization of AR inhibits mitotic AR degradation and next cycle of cell division [55]. This can 
explain biphasic effect of androgen on the cell-cycle progression of androgen-dependent prostate 
cancer cells [61]. Importantly, androgen-independent prostate cancer cells showed a prolonged  
half-life of AR in the absence of androgen [54], indicating that AR stabilization has a potential role in 
AR overexpression in CRPC. 
More recently, some molecules that are responsible for AR stabilization have been identified. 
Thomas and colleagues demonstrated that Stat5 (signal transducer and activator of transcription 5) 
stabilizes AR and potentiate castration-resistant progression of prostate cancer cells [62]. They also 
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found Stat5 expression is increased in high-grade disease or CRPC tissues. Cyclin-dependent kinases 
(Cdk) 1 [63] and 5 [64] were also reported to bind to and stabilize AR. Interestingly, Cdk5 stabilizes 
AR through phosphorylation of AR at Ser-81 [64], whereas Cdk1 does not require phosphorylation at 
Ser-81 for AR stabilization although it phosphorylates AR at Ser-81 [63]. Future studies will discover 
more molecules as a posttranslational modifier of AR, and elucidate their detailed roles in vivo for 
castration-resistant progression and identify potential targets in CRPC patients. 
7. Non-Specific Ligand Recognition (Figure 1C) 
AR sometimes recognizes steroidal or non-steroidal ligands other than testosterone or 
dihydrotestosterone like an agonist, which leads to aberrant activation of AR in the absence of 
androgen. Clinicians often observe apparently a paradoxical PSA decrease upon discontinuation of 
first generation non-steroidal anti-androgens including flutamide and bicalutamide, the so called  
“anti-androgen withdrawal syndrome (AWS)” first described by Kelly and Scher [65]. This 
phenomenon indicates that anti-androgens sometimes stimulate prostate cancer cells for PSA 
production, and probably AR-mediated proliferation, causing selection pressure that induces  
prostate cancer that can grow on anti-androgen. Veldscholte and colleagues discovered that  
androgen-dependent human prostate cancer LNCaP cells harbor the AR with single missense mutation 
on ligand-binding lesions (Thr877Ala) [66]. They demonstrated that androgens, progestagens, 
estrogens and anti-androgens bind the mutated androgen receptor protein and activate the expression 
of an androgen-regulated reporter gene. 
Hara and colleagues established a bicalutamide-resistant subline from LNCaP cells and found the 
cells harbor Trp741Cys/Leu mutation in the AR gene, which recognized bicalutamide as an agonist [67]. 
Our group established a patient-derived tumor graft line that expressed AR Trp741Cys that 
recapitulated AWS and effectiveness of alternative anti-androgen therapy in vivo [42,68]. Indeed,  
it was reported that 10%–30% of prostate cancers treated by anti-androgens acquired point mutation in 
the AR gene [69–72]. Thus, it has been believed that mutant AR is responsible for the “promiscuous” 
ligand recognition toward CRPC progression particularly under use of anti-androgens [73]. However, 
Chen and colleagues demonstrated that modest overexpression of AR also results in less specific 
ligand recognition on prostate cancer [40], indicating AWS can be expected in more cases with disease 
progression against anti-androgen administration. 
8. Ligand-Independent AR Activation (Figure 1D) 
Some clinical and experimental evidence indicate that there are several mechanisms that confer AR 
activation to prostate cancer cells relatively or completely independent (hereafter referred to as simply 
“ligand-independent”) of activating ligands. There are a number of co-factors for AR (extensively 
reviewed in ref. [74–76]), and some of them are overexpressed in CRPC and activate transcription by 
AR [77]. Recently, forkhead box protein A1 (FOXA1) has been shown to play an important role as AR 
co-regulator in prostate cancer. FOXA1 primarily an enhancer pioneer transcription factor and  
acts as a global mediator of steroid receptor action in hormone-dependent cancers including prostate 
cancer [78]. It was reported FOXA1 gene was amplified [79] and overexpressed [80,81] in metastatic 
prostate cancers and particularly in CRPC cases. Recent reports demonstrated that FOXA1 acted as an 
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AR cofactor to drive G2/M cell-cycle progression [82] and that AR and FOXA1 functionally cooperate 
and enhance proliferation and migration of prostate cancer cells [80] although there are conflicting 
reports on FOXA1 function in metastatic progression of prostate cancer [80,83]. 
Additionally, FOXA1 was shown to regulate a large number of genes considered to be  
AR-pathway-specific through binding and activating the glucocorticoid receptor [84]. In that context, 
activation of glucocorticoid receptor may promote CRPC progression whereas corticosteroids are used 
for CRPC patients to suppress adrenal androgens via an endocrinological negative feedback loop. 
Moreover, Zhang and colleagues showed that FOXA1 promote G1/S cell-cycle progression in an  
AR-independent manner [85]. According to a recent report by Jin and colleagues, FOXA1 requires the 
AR pathway to induce cell growth whereas it inhibits cell motility and epithelial-to-mesenchymal 
transition (EMT) in an AR-independent manner [83]. Another report showed a mutually inhibitory 
cross-talk between FOXA1 and SLUG1, a master regulator of EMT [86]. Recently, recurrent mutations 
in FOXA1 were observed on residues in the forkhead domain that resides near the DNA-binding 
surface [87] and the mutated FOXA1 was reported to increase tumor growth [88]. Thus, FOXA1 plays 
important roles in CRPC progression through co-regulating AR activity and distinct functions, 
however the role of FOXA1 in CRPC remains inconclusive and will be determined in the future. 
Posttranslational modifications including phosphorylation, acetylation, sumoylation, ubiquitination 
and methylation that contribute to ligand-independent activation of AR transcriptional activity  
have been widely studied [89,90]. Among those, phosphorylation is most extensively studied. Culig 
and colleagues demonstrated that, in human prostate cancer cells, various growth factors including 
insulin-like growth factor 1 (IGF-I), keratinocyte growth factor (KGF), and epidermal growth factor 
(EGF) directly activate the AR in the absence of androgens [91]. Indeed, Craft and colleagues found 
that castration-resistant xenograft sublines of human prostate cancer cells expressed higher levels of 
the HER-2/neu, receptor tyrosine kinase activated by EGF [92]. They also showed that overexpression 
of the HER-2/neu conferred castration-resistance to LAPC-4 and LNCaP cells via AR activation. As a 
downstream effector of HER-2/neu, MAP kinase was shown to upregulate AR transactivation through 
phosphorylation of AR at serine 514 resulting in the promotion of interaction between AR and AR 
coactivators, such as ARA70. Consistent with this, a siRNA phenotypic screen identified MAK3K11 
as a kinase regulating prostate cancer cell growth through modulating the AR transcriptional  
program [93]. Protein kinase A (PKA) is also known to phosphorylate and activate AR [94]. Our group 
showed that using a patient-derived tumor graft model, a prostaglandin E2 receptor EP4 conferred 
castration-resistance via activating PKA-AR signaling [43]. 
In addition to serine/threonine kinases, involvement of some tyrosine kinases has been  
suggested for castration-resistant activation of AR. Mahajan and colleagues found that activated 
Cdc42-associated tyrosine kinase (Ack1) phosphorylated AR protein at Tyr-267 and Tyr-363 and 
promoted castration-resistant growth of LNCaP and LAPC-4 xenograft tumors [95]. Guo and 
colleagues reported that Src tyrosine kinase phosphorylated AR and conferred castration resistance to 
prostate cancer cells upon EGF stimulation [96]. The same group demonstrated that overexpression of 
non-receptor tyrosine kinase Etk/BMX induced AR phosphorylation and castration resistance, 
suggesting that Etk/BMX is another tyrosine kinase of AR associated with castration-resistant 
progression of prostate cancer [97]. AR has been reported to bind to and activate Src in a  
ligand-dependent but non-transcriptional manner [98] and Src activation has been reported to activate 
Int. J. Mol. Sci. 2013, 14 15622 
 
other signaling pathways that confer androgen independence to LNCaP cells without affecting AR 
transactivation [99]. Thus, interaction between Src tyrosine kinase and AR seems complex and will be 
elucidated in the future studies. 
The PI3K/AKT pathway also plays complicated roles both in castration-naive and -resistant 
prostate cancers. Reports have shown that androgen withdrawal results in an increase of PI3K/AKT 
pathway activity both in cultured cells [100,101] and in vivo [102,103], which supports survival after 
androgen ablation. Although Wen and colleagues reported that activation of AKT upregulated AR 
transactivity [104], there have been conflicting reports that activation of AKT suppressed AR 
transactivity [102,103,105]. Additionally, activation of mTOR pathway, a main downstream effector 
of the PI3K/AKT pathway, was also reported to have oncogenic functions both in castration-naive and 
-resistant prostate cancers [106–108]. Cinar and colleagues reported that genetic or pharmacological 
downregulation of mTOR resulted in an increased abundance of AR protein, which is regulated by 
mRNA translation initiation [109]. Collectively, PI3K/AKT/mTOR pathway seems to contribute 
prostate cancer progression not through activation of AR but by facilitating survival of prostate  
cancer cells upon androgen deprivation. As another siRNA screen revealed, concomitant targeting of 
this pathway along with AR targeting therapy is a potentially effective strategy to eradicate prostate 
cancer [110]. 
Truncated AR species that composes only N-terminal domain (NTD) and DNA-binding domain 
(DBD) but lacks ligand-binding domain (LBD) and C-terminal domain (CTD) have been recently 
discovered as novel molecular mechanisms for the castration-resistant progression of prostate cancer.  
It was already known that 22Rv1 prostate cancer cells expressed smaller 75–80 kDa AR species that 
are distinct from wild-type ~112 kDa AR protein [111]. Antibody mapping revealed that the smaller 
AR lacks LBD and CTD. By a recent series of efforts based on 3'-rapid amplification of cDNA ends  
(3'-RACE), it was demonstrated that these AR truncates were coded by splice variants of AR mRNA 
harboring cryptic exons [112–115]. After some more additional isoforms were identified in VCaP cells 
by deep sequencing combined with 3'-RACE [116], more than 10 variants for truncated AR are known 
to date [117]. 
Indeed, the AR truncated variants are frequently found in CRPC tissues [118,119] and induced by 
androgen deprivation in prostate cancer cells [120]. Intragenic rearrangement of an AR genomic 
segment was proposed as a pathologic origin of the emergence and expansion of a subpopulation 
expressing high levels of truncated AR isoforms during CRPC progression [121,122]. Another group 
found that expression of truncated variants increased acutely in response to androgen withdrawal, 
indicating that the increase in AR variants expression in CRPC is an acute response to castration  
rather than clonal expansion of castration, or antiandrogen-resistant cells expressing gain of function 
AR variants [116]. In theory, these AR variants lacking LBD function as constitutively active in a 
ligand-independent manner, and prostate cancer cells expressing the AR variants are resistant to ADT 
including CYP17A inhibitors [117,123]. It was also reported that prostate cancer cells expressing the 
AR variants were resistant to the second-generation antiandrogen MDV3100 [124], whereas another 
study showed that castration-resistant growth mediated by the AR variants was blocked by MDV3100 
or by selective siRNA silencing of full-length AR, indicating that some AR truncated variants require 
full length AR to drive castration-resistant progression of prostate cancer [116]. 
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9. Targeting AR in CRPC; Promise and Peril 
Thus, AR drives CRPC progression in various fashions. Indeed, recent advances in transcriptome 
and genome revealed that AR is one of the most frequently altered genes in prostate cancer [88]. 
Moreover, AR mediates distinct transcription programs in CRPC from that in castration-naive prostate 
cancers. Wang and colleagues conducted chromatin immunoprecipitation (ChIP)-based screen for  
AR-dependent target genes in androgen-dependent and -independent prostate cancer cells and found 
that AR selectively upregulated M-phase cell-cycle genes in androgen-independent cells, including 
UBE2C, a gene that inactivates the M-phase checkpoint [82]. Similar study by another group also 
showed a distinct AR target gene set in CRPC cells [125]. Hu and colleagues showed that AR truncate 
variants mediates distinct transcription program from that mediated by ligand-dependent full-length 
AR [118]. Sharma and colleagues analyzed AR binding sites in human CRPC tissues and xenograft 
tumors and identified a number of AR binding sites, most of which were not identified in cell  
lines [126]. These data collectively indicates that AR is persistently functioning even under castrated 
condition but differentially regulating cellular function. It is also indicated that AR target genes are 
highly context-dependent and that it appears to be difficult to identify a single or a few genes that can 
be universally targetable elements in heterogeneous tumors. Therefore, it looks reasonable to target 
AR as a master regulator of androgen-dependent and -independent prostate cancer growth. 
With a castration-resistant status, prostate tumor models showed that AR is still required for 
growth. Chen and colleagues knocked down AR using short-hairpin RNA (shRNA)-expressing 
lentivirus in castration-resistant subline of LAPC-4 and LNCaP cells and showed the growth of 
xenograft tumors from both cells were retarded compared to control infected with control  
shRNA-expressing virus [40]. Another group used doxycycline-inducible shRNA system and observed 
similar findings on LNCaP cells [127]. Zhang and colleagues used antisense oligonucleotide that was 
shown to specifically downmodulate AR mRNA and protein and observed growth repression in a 
castration-resistant C4-2b xenograft model [128]. Since Chen and colleagues have shown the 
castration-resistant activation of AR required DNA-binding and nuclear translocation [40], the second 
generation antiandrogens are multitargeting; nuclear translocation, DNA-binding, recruitment of RNA 
Pol II as well as ligand binding [129,130]. 
Another effort is to target NTD that can theoretically and indeed cover AR truncate variants as a 
target [131]. NTD contains AF-1 region that plays an essential role for active transcription through 
interactions with other proteins including bridging factors and the basal transcriptional machinery. 
Currently three classes of these agents, small molecule [132], peptides [133], and decoy DNA [134], 
have been shown to suppress tumor growth in preclinical studies using xenograft models. As described 
above, using a gain-of-function miRNA screen and functional validation by Ostling and colleagues 
identified unique miRNAs that bound to 3'-UTR of AR mRNA and attenuated its expression [52]. This 
is also a potential strategy to inhibit AR function in CRPC. 
Some castration-resistant cell lines express little AR compared to their androgen-dependent  
parental lines [39,61] as well as primarily androgen-independent cell lines such as PC3 and DU145.  
In those cell lines, aberrant methylation of AR promoter is suggested as an associated molecular 
mechanism [135]. It was also reported that some CRPC patient-derived tumor grafts harbor features 
like small cell carcinoma and do not express AR [136]. In these models, some signaling pathways that 
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are regulated by AR in androgen-dependent cells seem to be aberrantly activated in an AR-independent 
manner [61,99]. Therefore, although there is no doubt AR plays a substantial role in the majority of 
CRPC, it should be noted that some CRPCs bypass the androgen/AR axis and have a proliferation 
signaling pathway activated. 
Figure 1. Schematic mechanisms for castration-resistant activation of the androgen 
receptor (AR). (A) De novo androgen synthesis results sustained levels of intratumoral 
androgens; (B) Genetic, epigenetic, post-transcriptional, or post-translational aberration 
that increases abundance of AR leads to ligand-independent activation or non-specific 
ligand recognition; (C) A mutation on the ligand-binding region also causes non-specific 
ligand recognition; (D) Truncated splice variants lacking the ligand-binding region,  
post-translational modification such as serine/threonine or tyrosine phosphorylation, or 
interaction with co-activating factors activates AR in a ligand-independent manner. 
 
10. Outlooks 
AR drives CRPC even under castrated serum androgen level. There are a variety of mechanisms for 
the castration-resistant activation of AR and the AR in CRPC regulates distinct gene sets from that in 
androgen-dependent prostate cancer. These indicate that AR persistently stays at the center of 
therapeutic targets even after castration-resistant progression of prostate cancer. 
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